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Background: Smoking enhances clopidogrel metabolism through induction of the CYP1A2 isoenzyme, resulting in enhanced pharmacodynamic 
effects in smoking compared with non-smoking patients. The aim of this study was to evaluate the association between smoking status and efficacy 
of antiplatelet therapy with clopidogrel or aspirin (ASA) for secondary prevention in a large cohort of patients with atherosclerotic vascular disease.
Methods: A total of 19,184 patients from the CAPRIE trial, which randomized patients with atherosclerotic vascular disease manifested as either 
recent ischemic stroke (IS), recent myocardial infarction (MI) or symptomatic peripheral artery disease (PAD) to ASA or clopidogrel therapy, were 
analyzed. The primary efficacy end point was the outcome event cluster of IS, MI, or vascular death. Smoking status was evaluated as collected 
(never smoked, ex-smokers, and current smokers), and combining never smoked/ex-smokers versus current smokers.
Results: In the overall population, current (n=5,688) and ex-smokers (n=9,381) had a numerically lower rate of ischemic events compared with 
patients who never smoked (n=4,135): 9.5%, 9.8% and 12.0%, respectively (p=0.30). However, after adjustment for baseline characteristics, an 
increased risk of ischemic events was observed in current smokers. When evaluated as a dichotomous variable (never smoked/ex-smokers versus 
current smokers), a significant interaction between smoking status and treatment was found (p=0.009). No significant difference in ischemic events 
with ASA was observed (never/ex versus current: 10.6% vs. 10.8%; p=0.14), whereas a trend towards a beneficial effect in current smokers with 
clopidogrel was seen (never/ex versus current: 10.4% vs. 8.3%; HR 0.87 [0.75-1.01]; p=0.06). This reached statistical significance in patients with 
previous MI (9.9%vs. 7.4%; HR 0.74 [0.56-0.97]; p=0.03). No interaction between study treatment and bleeding events was found.
Conclusions: In the CAPRIE population, a greater reduction of ischemic events among clopidogrel-treated patients was observed in current 
smokers compared with never smoked/ex-smoker patients, while this did not impact ASA-treated patients.
